Compounds > azacitidine

azacitidine and Anemia, Macrocytic

azacitidine has been researched along with Anemia, Macrocytic in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nohgawa, M; Oka, S; Ono, K1
Curtis, SA; Folkers, A; Medoff, E; Mixon, R; Shallis, RM; Xu, ML; Zeidan, AM1
Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A1
Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H1
Sanchez, JF1
Czepulkowski, B; Gäken, J; Ireland, R; Krishnamurthy, P; Kulasekararaj, AG; Lea, NC; Marsh, JC; Mian, SA; Mohamedali, AM; Mufti, GJ; Pennaneach, C; Pomplun, S; Smith, AE1

Reviews

3 review(s) available for azacitidine and Anemia, Macrocytic

ArticleYear
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Annals of hematology, 2018, Volume: 97, Issue:11

    Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood Transfusion; Breast Neoplasms; Female; Humans; Hydroxyurea; Isocitrate Dehydrogenase; Jehovah's Witnesses; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms, Second Primary; Treatment Refusal

2018
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    International journal of hematology, 2017, Volume: 105, Issue:5

    Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic

2017
Treatment of myelodysplastic syndromes in elderly patients.
    Advances in therapy, 2011, Volume: 28 Suppl 2

    Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide

2011

Other Studies

3 other study(ies) available for azacitidine and Anemia, Macrocytic

ArticleYear
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Annals of hematology, 2017, Volume: 96, Issue:8

    Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; In Situ Hybridization, Fluorescence; Janus Kinase 2; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation, Missense; Neoplasms, Multiple Primary; Remission Induction; Translocation, Genetic

2017
Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:5

    Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocythemia, Essential; Treatment Outcome

2013
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
    British journal of haematology, 2013, Volume: 160, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antimetabolites; Azacitidine; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Follow-Up Studies; Genes, p53; Humans; Incidence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Risk; Treatment Outcome; Young Adult

2013